Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) — Market Cap & Net Worth
Market Cap & Net Worth: Ligand Pharmaceuticals Incorporated (LGND)
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has a market capitalization of $3.62 Billion ($3.62 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4401 globally and #1434 in its home market, demonstrating a -0.46% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ligand Pharmaceuticals Incorporated's stock price $227.44 by its total outstanding shares 19681720 (19.68 Million). Analyse cash efficiency ratio of Ligand Pharmaceuticals Incorporated to see how efficiently the company converts income to cash.
Ligand Pharmaceuticals Incorporated Market Cap History: 2015 to 2026
Ligand Pharmaceuticals Incorporated's market capitalization history from 2015 to 2026. Data shows growth from $1.33 Billion to $4.48 Billion (13.80% CAGR).
Index Memberships
Ligand Pharmaceuticals Incorporated is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.15% | #99 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.01% | #477 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.22% | #64 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.54 Trillion | 0.17% | #126 of 602 |
Weight: Ligand Pharmaceuticals Incorporated's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ligand Pharmaceuticals Incorporated Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ligand Pharmaceuticals Incorporated's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
12.62x
Ligand Pharmaceuticals Incorporated's market cap is 12.62 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.33 Billion | $71.91 Million | $257.31 Million | 18.51x | 5.17x |
| 2016 | $1.25 Billion | $108.97 Million | -$1.64 Million | 11.45x | N/A |
| 2017 | $1.68 Billion | $141.10 Million | $12.56 Million | 11.92x | 133.90x |
| 2018 | $1.67 Billion | $251.45 Million | $143.32 Million | 6.63x | 11.63x |
| 2019 | $1.28 Billion | $120.28 Million | $629.30 Million | 10.65x | 2.03x |
| 2020 | $1.22 Billion | $163.56 Million | -$2.98 Million | 7.47x | N/A |
| 2021 | $1.90 Billion | $241.54 Million | $57.14 Million | 7.85x | 33.19x |
| 2022 | $1.31 Billion | $196.25 Million | -$33.36 Million | 6.70x | N/A |
| 2023 | $1.41 Billion | $131.31 Million | $52.15 Million | 10.70x | 26.95x |
| 2024 | $2.11 Billion | $167.13 Million | -$4.03 Million | 12.62x | N/A |
Competitor Companies of LGND by Market Capitalization
Companies near Ligand Pharmaceuticals Incorporated in the global market cap rankings as of May 2, 2026.
Key companies related to Ligand Pharmaceuticals Incorporated by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Ligand Pharmaceuticals Incorporated Historical Marketcap From 2015 to 2026
Between 2015 and today, Ligand Pharmaceuticals Incorporated's market cap moved from $1.33 Billion to $ 4.48 Billion, with a yearly change of 13.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.48 Billion | +20.29% |
| 2025 | $3.72 Billion | +76.45% |
| 2024 | $2.11 Billion | +50.03% |
| 2023 | $1.41 Billion | +6.92% |
| 2022 | $1.31 Billion | -30.67% |
| 2021 | $1.90 Billion | +55.31% |
| 2020 | $1.22 Billion | -4.64% |
| 2019 | $1.28 Billion | -23.15% |
| 2018 | $1.67 Billion | -0.90% |
| 2017 | $1.68 Billion | +34.76% |
| 2016 | $1.25 Billion | -6.28% |
| 2015 | $1.33 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Ligand Pharmaceuticals Incorporated was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.62 Billion USD |
| MoneyControl | $3.62 Billion USD |
| MarketWatch | $3.62 Billion USD |
| marketcap.company | $3.62 Billion USD |
| Reuters | $3.62 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for r… Read more